US Stocks Movement: CRISPR Therapeutics plunges on November 12th as Q3 losses widen, CTX310 data-driven pullback, and executive share sales

CRISPR Therapeutics November 12 Steep Drop Analysis

Keywords: Widened Q3 Loss, Pre-CTX310 Data Pullback, Executive Share Sale

1. On November 2, CRISPR Therapeutics released its Q3 2026 financial results, reporting a loss of $1.15 per share, higher than the market expectation of $1.06, with a net loss of $111.4 million compared to $106.4 million in the same period last year.

2. Core pipeline CTX310’s phase 1b data for treating severe hypertriglyceridemia is scheduled to be presented at the AHA annual meeting on November 9. Uncertainty before data release and profit-taking pressure led to a pullback.

3. Company executive Raju Prasad filed a Form 144 on November 6, intending to sell 79,393 common shares, involving approximately $3.96 million.

4. On November 2, the company appointed Siva Sakhamuri as Chief Technical Officer. Combined with continued quarterly net losses, market doubts have arisen regarding the alignment between valuation and book value.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)